S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells
- 338 Downloads
Many transformed cells and embryonic stem cells are dependent on the biosynthesis of the universal methyl-donor S-adenosylmethionine (SAM) from methionine by the enzyme MAT2A to maintain their epigenome. We hypothesized that cancer stem cells (CSCs) rely on SAM biosynthesis and that the combination of methionine depletion and MAT2A inhibition would eradicate CSCs.
Human triple (ER/PR/HER2)-negative breast carcinoma (TNBC) cell lines were cultured as CSC-enriched mammospheres in control or methionine-free media. MAT2A was inhibited with siRNAs or cycloleucine. The effects of methionine restriction and/or MAT2A inhibition on the formation of mammospheres, the expression of CSC markers (CD44hi/C24low), MAT2A and CSC transcriptional regulators, apoptosis induction and histone modifications were determined. A murine model of metastatic TNBC was utilized to evaluate the effects of dietary methionine restriction, MAT2A inhibition and the combination.
Methionine restriction inhibited mammosphere formation and reduced the CD44hi/C24low CSC population; these effects were partly rescued by SAM. Methionine depletion induced MAT2A expression (mRNA and protein) and sensitized CSCs to inhibition of MAT2A (siRNAs or cycloleucine). Cycloleucine enhanced the effects of methionine depletion on H3K4me3 demethylation and suppression of Sox9 expression. Dietary methionine restriction induced MAT2A expression in mammary tumors, and the combination of methionine restriction and cycloleucine was more effective than either alone at suppressing primary and lung metastatic tumor burden in a murine TNBC model.
Our findings point to SAM biosynthesis as a unique metabolic vulnerability of CSCs that can be targeted by combining methionine depletion with MAT2A inhibition to eradicate drug-resistant CSCs.
KeywordsMethionine Breast cancer S-adenosylmethionine Nutrition Cancer stem cell Therapeutics
We are indebted to members of the Cryns lab for their critical reading of the manuscript.
This work was supported by Grants from the Breast Cancer Research Foundation (VLC), V Foundation for Cancer Research (VLC), the Sidney Kimmel Foundation for Cancer Research (PWL), Wisconsin Partnership Program (VLC), National Institutes of Health grant P41GM108538 (JJC), University of Wisconsin Comprehensive Cancer Center Pilot Award (VLC and PWL) and P30CA14520 core facility support. We also acknowledge financial support from the Morgridge Institute for Research Metabolism Theme.
Compliance with ethical standards
Conflict of interest
JJC is a consultant for Thermo Fisher Scientific. The other authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
- 7.Kreis W, Baker A, Ryan V, Bertasso A (1980) Effect of nutritional and enzymatic methionine deprivation upon human normal and malignant cells in tissue culture. Cancer Res 40:634–641Google Scholar
- 8.Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM (1993) Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res 53:5676–5679Google Scholar
- 9.Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y et al (1995) Human tumors are methionine dependent in vivo. Anticancer Res 15:717–718Google Scholar
- 10.Lu S, Hoestje SM, Choo E, Epner DE (2003) Induction of caspase-dependent and -independent apoptosis in response to methionine restriction. Int J Oncol 22:415–420Google Scholar
- 15.Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E et al (2007) A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res 27:2779–2783Google Scholar
- 25.Sufrin JR, Coulter AW, Talalay P (1979) Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-adenosyl-l-methionine. IV. Further mono-, bi- and tricyclic amino acids. Mol Pharmacol 15:661–677Google Scholar
- 30.Guarino AM, Rozencweig M, Kline I, Penta JS, Venditti JM, Lloyd HH et al (1979) Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. Cancer Res 39:2204–2210Google Scholar
- 31.Savlov ED, MacIntyre JM, Knight E, Wolter J (1981) Comparison of doxorubicin with cycloleucine in the treatment of sarcomas. Cancer Treat Rep 65:21–27Google Scholar